Earnings Summary

Singular Genomics Systems In’s revenue jumped 41.31% since last year same period to $1.08Mn in the Q4 2023. On a quarterly growth basis, Singular Genomics Systems In has generated 133.98% jump in its revenue since last 3-months.

Singular Genomics Systems In’s net profit fell -18.18% since last year same period to $-23.25Mn in the Q4 2023. On a quarterly growth basis, Singular Genomics Systems In has generated -3.98% fall in its net profits since last 3-months.

Singular Genomics Systems In’s net profit margin jumped 16.36% since last year same period to -2150.69% in the Q4 2023. On a quarterly growth basis, Singular Genomics Systems In has generated 55.56% jump in its net profit margins since last 3-months.

Singular Genomics Systems In’s earning per share (EPS) estimates for the current quarter stand at -0.35 - a -2.94% fall from last quarter’s estimates.

Singular Genomics Systems In’s earning per share (EPS) estimates for the current year stand at -0.35.

Singular Genomics Systems In’s earning per share (EPS) fell -10.34% since last year same period to -0.32 in the Q4 2023. This indicates that the Singular Genomics Systems In has generated -10.34% annual rate of fall in its earning per share (EPS) in the last 4 quarters.

Return on assets (ROA) indicates the profitability of the company in relation to its total assets. This ratio tells the financial health of the company. The higher the ROA, the better the company’s financial health. If any company has a ROA in the range of 5% to 20% - it is generally considered good. ROA above 20% is generally considered excellent. Singular Genomics Systems In’s return on assets (ROA) stands at -0.21.

The Return On Equity ratio indicates a company’s ability to turn equity capital received from shareholders into profits. ROE highlights the efficiency of equity capital in running the business. Generally, a return on equity in double digits is considered good. Singular Genomics Systems In’s return on equity (ROE) stands at -0.43.